What is Kala Bio?
Kala Bio, founded in 2009 and headquartered in Arlington, Massachusetts, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics. The company's focus lies in creating novel drug delivery systems and treatments for various medical conditions, aiming to address unmet patient needs through scientific advancement.
How much funding has Kala Bio raised?
Kala Bio has raised a total of $104.8M across 4 funding rounds:
Stock Offering
$90M
Share Placement
$10.8M
Private Equity
$2.3M
Private Equity
$1.8M
Stock Issuance/Offering (2017): $90M, investors not publicly disclosed
Share Placement (2024): $10.8M, investors not publicly disclosed
Private Equity (2026): $2.3M, investors not publicly disclosed
Private Equity (2026): $1.8M, investors not publicly disclosed
What's next for Kala Bio?
With the recent major strategic investment, Kala Bio is poised for accelerated growth and expansion. The company is expected to leverage this capital to advance its pipeline, potentially scale its operations, and further its research and development initiatives. This funding will likely enable Kala Bio to move closer to commercializing its therapeutic candidates and solidify its position in the competitive biopharmaceutical landscape.
See full Kala Bio company page
